Biodevek Inc.
Boston, MA
- UEI
- C16MAJV41YM5
- CAGE
- 8J5V5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 127 Western Ave, Boston, MA 02134, USA
- Website
- biodevek.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: sprayable hydrogel sealant for gastrointestinal wound protection -the broader impact/commercial potential… | National Science Foundation | $1,250,000 | |
| Production of a hydrogel-based mucosal sealant for gastrointestinal bleeding prevention - abstract gastrointestinal (GI)… | National Institute of Diabetes and Digestive and Kidney Diseases | $3,050,058 | |
| Sbir phase i: sprayable hydrogel sealant for gastrointestinal wound protection -the broader impact/commercial… | National Science Foundation | $275,000 |
About Biodevek Inc.
Biodevek Inc. is a Boston-based small business focused on developing innovative medical technologies, specifically advanced hydrogel-based solutions for medical applications. Registered in SAM.gov as a for-profit corporate entity, the company specializes in research and development of cutting-edge biomedical technologies with a particular emphasis on gastrointestinal medical interventions. The company has demonstrated significant technological innovation through its development of sprayable hydrogel sealants designed to address critical medical challenges in wound management and surgical procedures.
Biodevek Inc. has secured multiple federal grants from prominent agencies like the National Science Foundation (NSF) and the National Institute of Diabetes and Digestive and Kidney Diseases, focusing exclusively on developing advanced hydrogel technologies for gastrointestinal medical applications. Their primary product, GastroShield, is a sprayable biocompatible adhesive biomaterial designed for endoscopic management of gastrointestinal lesions. The company has progressed through SBIR Phase I and Phase II grants, with awards totaling at least $1,250,000, to develop and refine a hydrogel sealant that can prevent bleeding, protect surgical wounds, and provide a more effective alternative to traditional endoscopic clip technologies. Their research aims to address significant medical challenges, including reducing post-surgical complications, improving wound healing, and potentially reducing healthcare costs associated with gastrointestinal procedures. The grants support comprehensive research involving formulation optimization, mechanical studies, biocompatibility testing, and preclinical trials, with the ultimate goal of obtaining FDA 510(k) regulatory approval for their innovative medical technology.
Quick answers
What is Biodevek Inc.'s UEI?
Biodevek Inc.'s Unique Entity ID (UEI) in SAM.gov is C16MAJV41YM5.
What is Biodevek Inc.'s CAGE code?
Biodevek Inc.'s CAGE code is 8J5V5.
Where is Biodevek Inc. located?
Biodevek Inc.'s physical address in SAM.gov is 127 Western Ave, Boston, MA 02134, USA.
Is Biodevek Inc. registered in SAM.gov?
Yes. Biodevek Inc.'s SAM.gov registration is active through March 24, 2027.
What is Biodevek Inc.'s most recent federal award?
Biodevek Inc.'s most recent federal grant award is Sbir phase II: sprayable hydrogel sealant for gastrointestinal wound protection -the broader impact/commercial potential… (2451674), from National Science Foundation, on April 15, 2025.
On GovTribe
See Biodevek Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors